RAD18 and cancer: Based on our result that mutation of the major RAD18 O-GlcNAcylation residues sensitizes cell to CPT exposure, it is reasonable to speculate that targeting RAD18 O-GlcNAcylation in cancer cells may have potential therapeutic benefits.